Browse AMN

Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Apical cell membrane Single-pass type I membrane protein Cell membrane Peripheral membrane protein Endosome Membrane, coated pit
Domain PF14828 Amnionless
Function

Necessary for efficient absorption of vitamin B12 (PubMed:12590260, PubMed:14576052). Required for normal CUBN-mediated protein transport in the kidney. May direct the production of trunk mesoderm during development by modulating a bone morphogenetic protein (BMP) signaling pathway in the underlying visceral endoderm (By similarity).

> Gene Ontology
 
Biological Process GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006898 receptor-mediated endocytosis
GO:0007009 plasma membrane organization
GO:0007588 excretion
GO:0009235 cobalamin metabolic process
GO:0015889 cobalamin transport
GO:0033013 tetrapyrrole metabolic process
GO:0042157 lipoprotein metabolic process
GO:0043001 Golgi to plasma membrane protein transport
GO:0051180 vitamin transport
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:1990778 protein localization to cell periphery
Molecular Function -
Cellular Component GO:0005905 clathrin-coated pit
GO:0010008 endosome membrane
GO:0016324 apical plasma membrane
GO:0030139 endocytic vesicle
GO:0044440 endosomal part
GO:0045177 apical part of cell
GO:0098589 membrane region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-196741: Cobalamin (Cbl, vitamin B12) transport and metabolism
R-HSA-3359462: Defective AMN causes hereditary megaloblastic anemia 1
R-HSA-3359463: Defective CUBN causes hereditary megaloblastic anemia 1
R-HSA-3296469: Defects in cobalamin (B12) metabolism
R-HSA-3296482: Defects in vitamin and cofactor metabolism
R-HSA-1643685: Disease
R-HSA-5668914: Diseases of metabolism
R-HSA-194223: HDL-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AMN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AMN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AMN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5710.23
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1720.828
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.120.0976
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9162.2550.000523
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.8810.172
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472.7290.104
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.380.629
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3780.323
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7930.583
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.0110.546
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.1630.594
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1970.418
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AMN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AMN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AMN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AMN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AMN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AMN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AMN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAMN
Nameamnion associated transmembrane protein
Aliases amnionless; amnionless homolog (mouse); PRO1028; amnionless homolog; visceral endoderm-specific type 1 trans ......
Chromosomal Location14q32.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AMN collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AMN.
ID Name Drug Type Targets #Targets
DB00200HydroxocobalaminSmall MoleculeAMN, CUBN, MMAA, MMAB, MMACHC, MTR, MTRR, MUT, TCN19